- Home
- GMAB vs DT Comparison
GMAB vs DT Comparison
Compare GMAB & DT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- DT
- Stock Information
- Founded
- GMAB 1999
- DT 2005
- Country
- GMAB Denmark
- DT United States
- Employees
- GMAB N/A
- DT N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- DT Computer Software: Prepackaged Software
- Sector
- GMAB Health Care
- DT Technology
- Exchange
- GMAB Nasdaq
- DT Nasdaq
- Market Cap
- GMAB 15.0B
- DT 13.2B
- IPO Year
- GMAB N/A
- DT 2019
- Fundamental
- Price
- GMAB $20.65
- DT $55.46
- Analyst Decision
- GMAB Buy
- DT Buy
- Analyst Count
- GMAB 8
- DT 25
- Target Price
- GMAB $43.00
- DT $60.50
- AVG Volume (30 Days)
- GMAB 1.4M
- DT 3.5M
- Earning Date
- GMAB 11-06-2024
- DT 11-07-2024
- Dividend Yield
- GMAB N/A
- DT N/A
- EPS Growth
- GMAB 14.35
- DT N/A
- EPS
- GMAB 10.80
- DT 0.54
- Revenue
- GMAB $2,967,926,227.00
- DT $1,563,293,000.00
- Revenue This Year
- GMAB $30.31
- DT $20.03
- Revenue Next Year
- GMAB $16.49
- DT $15.61
- P/E Ratio
- GMAB $18.68
- DT $102.73
- Revenue Growth
- GMAB 17.75
- DT 20.58
- 52 Week Low
- GMAB $20.34
- DT $39.42
- 52 Week High
- GMAB $32.88
- DT $61.41
- Technical
- Relative Strength Index (RSI)
- GMAB 29.22
- DT 59.25
- Support Level
- GMAB $20.34
- DT $50.09
- Resistance Level
- GMAB $23.47
- DT $54.42
- Average True Range (ATR)
- GMAB 0.46
- DT 1.76
- MACD
- GMAB -0.12
- DT -0.08
- Stochastic Oscillator
- GMAB 9.90
- DT 73.56
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About DT Dynatrace Inc.
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.